Telephus Medical LLC Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We welcome the chance to interact with many of world’s leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.

San Diego, CA (PRWEB) April 22, 2014

Telephus Medical LLC, a company focused on preventing periprosthetic infections after total joint replacement surgery, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 in New York, NY. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and select private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Michael Moffat, Cavendish co-founder and President explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Telephus’ research and scientific insights into the prevention of periprosthetic joint infections positions them to make a major contribution towards the reduction and elimination of bone infections and accompanying osteomyelitis that sometimes arise as serious complications from joint replacement surgery and other orthopedic procedures.”

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative focus on developing new products for the prevention of orthopedic infections. Periprosthetic joint infection is the leading cause of total knee replacement revision and the second-leading cause of hip replacement revision surgery around the world today,” said Mark Benedyk, PhD, President and CEO of Telephus. “Treatment costs of these complications in the United States alone are projected to exceed $1.6 billion by 2020. We welcome the chance to interact with many of world’s leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.

About Telephus Medical LLC

Telephus is developing TPH 101, a first-in-class humanized neutralizing monoclonal antibody to prevent staphylococcal infections and accompanying osteomyelitis in patients receiving total hip arthroplasty or total knee arthroplasty septic revision surgery. Focused on preventing the early events that lead to implantable device infections, we are dedicated to improving patient outcomes for orthopedic procedures – addressing a large and growing unmet medical need in a world where people are living longer, more active lives through joint replacement surgery.

Telephus was founded in 2012 and is based in San Diego, California.

Further information is available at http://www.telephusmedical.com.

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States (taking place in New York at the United Nations Headquarters May 5th to 7th 2014), Europe (London, October 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015).

For more information: http://cavendishglobal.com


Contact